Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
Whole Genome Sequencing, Myelodysplastic Syndromes
About this trial
This is an interventional diagnostic trial for Whole Genome Sequencing
Eligibility Criteria
Inclusion Criteria Patient:
- Diagnosis of MDS, or a clinical suspicion for a new diagnosis of MDS, for whom routine diagnostic testing is requested or planned to be requested.
- Seen in the outpatient setting.
- Not been previously treated with disease-modifying therapy (such as lenalidomide or hypomethylating agents).
Note: Patients who have received transfusional support, erythropoietin-stimulating agents, growth factor support, or luspatercept are eligible.
At least 18 years of age.
-Able to understand and willing to sign an IRB approved written informed consent document.
Inclusion Criteria Physician:
- Treating physician at Washington University School of Medicine who directs therapy for individuals with hematologic malignancies.
- Able and willing to complete standardized questionnaires about stakeholder perceptions of ChromoSeq during the ChromoSeq implementation process. (Written documentation of informed consent is not required.)
Exclusion Criteria Patient:
-Younger than 18 years of age
Exclusion Criteria Physician
-Does not treat patients at Washington University School of Medicine
Sites / Locations
- Washington University School of MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Patients: ChromSeq
Stakeholders (Treating Physicians)
ChromoSeq will be performed on bone marrow or peripheral blood DNA from consented patients in parallel with the standard of care cytogenetics, FISH, and the MyeloSeq gene panel obtained from that sample, in a CLIA licensed environment using CLIA-compliant ChromoSeq procedures.
Stakeholders (treating physicians) will complete surveys/questionnaires